Wednesday, April 24, 2024

Verve Therapeutics stock plunges as cholesterol-lowering gene-editing treatment faces setback

Must read




Verve Therapeutics shares dropped more than 30% early Tuesday after the company paused enrollment in a trial of its gene-editing treatment for heart disease.



Source link

More articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest article